Home›Stock Screener›Advanced Enzyme Tech

Advanced Enzyme Tech Share Price Today | Stock Price & Advanced Enzyme Tech Share Screener

ADVENZYMES Pharmaceuticals & Biotechnology
Live Share Price NSE
₹281.00
▼ -2.15 (-0.76%)
2026-11-18 00:00:00
Live Share Price BSE
₹281.10
▼ -1.90 (-0.67%)
2026-11-18 00:00:00

As of November 18, 2026, the live Advanced Enzyme Tech share price (NSE: ADVENZYMES) is ₹281.00 on NSE and ₹281.10 on BSE, down 0.76% from the previous close, with shares trading between ₹276.50 and ₹284.00 in today's trading session, and a 52-week range of ₹248.35–₹392.10. Track ADVENZYMES company valuation to gauge the company's total market size. Use the Advanced Enzyme Tech stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Advanced Enzyme Tech opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹223 and net income of ₹51, with EBITDA of ₹81, an operating margin of 34.0% and a profit margin of 22.9%.

Advanced Enzyme Tech Market Cap ₹3,131.13 Cr.
ADVENZYMES P/E Ratio (TTM) 17.40
Advanced Enzyme Tech P/B Ratio 1.86
EPS (TTM) ₹15.08
Dividend Yield 1.90%
Debt to Equity 0.02
ADVENZYMES 52 Week High ₹392.10
Advanced Enzyme Tech 52 Week Low ₹248.35
Operating Margin 34.00%
Profit Margin 22.87%
ADVENZYMES Revenue (TTM) ₹223.00
EBITDA ₹81.00
Net Income ₹51.00
Total Assets ₹1,839.00
Total Equity ₹1,683.00

Advanced Enzyme Tech Share Price Chart

Track the current stock price of Advanced Enzyme Tech with an interactive chart. Analyse ADVENZYMES share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Advanced Enzyme Tech stock quote in one place.

The quote of ₹281.00 sits between the 52-week low of ₹248.35 and the 52-week high of ₹392.10, and the latest session moved -0.76% from the previous close.

Advanced Enzyme Tech Company Profile - Fundamental Screener

Screen Advanced Enzyme Tech company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for ADVENZYMES shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE837H01020.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE837H01020

Advanced Enzyme Tech Balance Sheet Screener

Screen ADVENZYMES balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹1,839, up from ₹1,621 in 2025.

Latest statistics put total assets at ₹1,839 and shareholder funds at ₹1,683, with a leverage ratio of 0.02.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 1,839 1,621 1,536 1,422 1,268 1,153 979 811 732 589
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 692 679 650 649 619 601 563 496 491 421

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 49 56 58 60 67 54 52 41 51 42
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 1,683 1,469 1,371 1,284 1,140 1,031 867 705 582 485
Share Capital 22 22 22 22 22 22 22 22 22 22
Reserves & Surplus 1,609 1,399 1,302 1,213 1,066 948 817 657 537 442

Advanced Enzyme Tech Income Statement Screener - Profit & Revenue Analysis

Screen Advanced Enzyme Tech income statement and profit fundamentals. Analyze ADVENZYMES quarterly results. Advanced Enzyme Tech reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Sept, revenue was ₹223 and net profit was ₹51, equal to earnings per unit of ₹4.33, at an operating margin of 34%.

In that period expenses were ₹142, interest cost ₹1 and tax ₹18. The next period listed, 2026-Jun, shows revenue of ₹203 and net profit of ₹39.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun 2024-Mar 2023-Dec 2023-Sept 2023-Jun 2023-Mar

Revenue and Expenses

Revenue 223 203 211 192 195 195 176 177 156 162 167 175 164 154 150
Expenses 142 139 140 123 125 130 122 114 104 103 118 107 107 103 99

Operating Costs and Margins

EBITDA 81 64 71 69 70 65 54 63 52 58 50 68 57 51 51
Operating Profit % 34.00% 28.00% 31.00% 29.00% 33.00% 30.00% 27.00% 33.00% 29.00% 33.00% 26.00% 33.00% 33.00% 30.00% 29.00%
Depreciation 11 10 10 10 10 10 10 9 9 9 9 9 9 9 8
Interest 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1

Profit and Earnings

Profit Before Tax 69 54 60 58 60 55 44 53 42 49 40 59 48 41 42
Tax 18 15 15 15 15 15 17 14 9 14 10 16 13 12 10
Net Profit 51 39 45 43 45 40 27 39 33 35 30 43 35 29 32
EPS 4.33 3.31 3.84 3.80 3.87 3.57 2.37 3.36 2.94 3.05 2.53 3.74 3.08 2.58 2.87

Advanced Enzyme Tech Cash Flow Screener - Liquidity Fundamentals

Screen ADVENZYMES cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹157, and net cash flow was an inflow of ₹15.

Over the same period, investing activities used ₹72 and financing activities used ₹70.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 157 143 141 140 122 163 141 129 116 107
Investing Activities -72 -90 -65 -286 2 -27 -43 -124 -60 -60

Financing and Net Cash

Financing Activities -70 -73 -59 -26 -49 -26 -39 -43 -2 -65
Net Cash Flow 15 -20 17 -171 75 109 60 -38 54 -18

Advanced Enzyme Tech Shareholding Pattern Screener

See Advanced Enzyme Tech shareholding pattern with promoter, FII, and DII holdings. Check Advanced Enzyme Tech promoter holding and ownership changes for ADVENZYMES on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 43.26%, foreign institutions 25.49%, domestic institutions 5.41% and the public 17.57%, spread across 66,193 shareholders.

The shareholder count was 66,193 in 2026-Mar, compared with 63,599 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar

Promoter Holding

Promoter Holding 43.26% 43.24% 43.56% 43.08% 43.08% 43.07% 43.04% 43.49%

Institutional Investors

FII Holding 25.49% 26.71% 26.65% 11.90% 23.46% 25.41% 25.86% 23.01%
DII Holding 5.41% 4.78% 1.89% 8.19% 8.45% 6.41% 5.51% 7.56%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 17.57% 16.94% 18.65% 16.68% 16.92% 16.95% 17.44% 15.43%
Other Holding 8.26% 8.33% 9.25% 20.16% 8.10% 8.15% 8.15% 10.51%
Shareholder Count 66,193 63,599 67,468 65,322 67,589 69,637 68,051 68,640

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Advanced Enzyme Tech. Advanced Enzyme Tech dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹5.35 per unit for 2026-March, a yield of 1.90%, compared with ₹5.20 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹5.35, ₹5.20 and ₹5.10 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹5.35 1.90%
2025-March ₹5.20 2.04%
2024-March ₹5.10 1.83%
2023-March ₹1.00 0.29%
2022-March ₹1.00 0.42%
2021-March ₹0.90 0.32%
2020-March ₹0.60 0.17%
2019-March ₹0.60 0.42%
2018-March ₹0.50 0.27%
2017-March ₹0.40 0.19%

Advanced Enzyme Tech Stock Index Membership - Nifty & Sensex

See which indices include Advanced Enzyme Tech stock. Check ADVENZYMES index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 5 indices, including BSE 1000.

Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX SMLCAP, NIFTY MICROCAP250.

Complete Index List

BSE 1000
BSE INDEX BSE HC
BSE INDEX SMLCAP
NIFTY MICROCAP250
NIFTY TOTAL MKT

Advanced Enzyme Tech Market Events Screener - Corporate Actions

Get Advanced Enzyme Tech corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Advanced Enzyme Tech stock events that may affect ADVENZYMES share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated October 31, 2026, with a record date of October 31, 2026.

It is followed by Quarterly Result Announcement dated August 8, 2026 and Annual General Meeting dated July 31, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-10-31 2026-10-31 Quarterly Result Announcement NA 1.82%
2026-08-08 2026-08-08 Quarterly Result Announcement NA 2.95%
2026-07-31 2026-07-31 Annual General Meeting NA -2.49%
2026-07-24 2026-07-24 Dividend ₹ 1.35 /share -12.04%
2026-05-09 2026-05-09 Quarterly Result Announcement NA 2.67%
2026-01-31 2026-01-31 Quarterly Result Announcement NA 9.05%
2025-11-12 2025-11-12 Quarterly Result Announcement NA -3.24%
2025-08-02 2025-08-02 Quarterly Result Announcement NA 9.08%
2025-07-30 2025-07-30 Annual General Meeting NA 17.48%
2025-07-23 2025-07-23 Dividend ₹ 1.20 /share 14.47%
2025-05-16 2025-05-17 Dividend ₹ 4.00 /share -2.19%
2025-05-13 2025-05-13 Quarterly Result Announcement NA 3.73%
2025-02-08 2025-02-08 Quarterly Result Announcement NA 0.59%
2024-11-09 2024-11-09 Quarterly Result Announcement NA 8.58%
2024-07-25 2024-07-25 Annual General Meeting NA -0.83%

Advanced Enzyme Tech Competitors Screener - Peer Stocks Comparison

Screen ADVENZYMES competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 451,939 40.80 61,674 12.69% 11,565 59.98
Divis Laboratories 295,307 87.70 11,067 13.95% 2,568 67.88
Torrent Pharmaceuticals 176,947 85.00 13,886 20.34% 2,138 49.31
Laurus Labs 125,379 89.90 6,868 22.01% 890 49.19
Zydus Life Science 120,479 27.60 27,658 17.64% 5,026 52.87
Dr Reddys Laboratories 115,011 41.80 35,059 3.90% 4,158 69.34
Cipla 112,510 39.50 29,045 2.24% 3,870 55.82
Mankind Pharma 108,503 47.90 14,636 14.85% 1,938 63.62
Aurobindo Pharma 103,240 25.80 34,145 5.56% 3,503 60.38
Lupin 89,647 17.30 29,039 26.75% 5,356 44.23

Advanced Enzyme Tech Company Announcements - News & Reports Screener

Screen ADVENZYMES latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 5, 2026.

The next most recent announcements are dated November 5, 2026 and November 3, 2026.

Date Update Actions
2026-11-05 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-11-05 Corporate Action-Updates on Buy back -
2026-11-03 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-11-03 Announcement under Regulation 31A (LODR)-(8)(c) Submission of application to Exchange -
2026-11-02 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-10-31 Announcement under Regulation 30 (LODR)-Post Buyback Public Announcement -
2026-10-31 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-10-31 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-10-31 Announcement under Regulation 31A (LODR)-(8)(b) Outcome of Board Meeting -
2026-10-31 Unaudited Financial Results (Standalone & Consolidated) Of The Company For The Quarter And Half Year Ended September 30 2026 -
2026-10-31 Board Meeting Outcome for Outcome Of Board Meeting Held On October 31 2026 -
2026-10-30 Announcement under Regulation 30 (LODR)-Closure of Buy Back -
2026-10-30 Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares -
2026-10-29 Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares -
2026-10-28 Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares -
2026-10-27 Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares -
2026-10-26 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-26 Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares -
2026-10-23 Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares -
2026-10-23 Board Meeting Intimation for The Approval Of Un-Audited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30 2026 -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹281.00, within a 52-week range of ₹248.35 to ₹392.10. The P/E ratio is 17.40 and the P/B ratio is 1.86, with earnings per unit of ₹15.08. Market capitalisation stands at ₹3,131.13 Cr and the dividend yield is 1.90%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 19, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.